Can tirzepatide or semaglutide be used in type 1 diabetes?
Not as an approved use. No label we read lists type 1 diabetes as a use for tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy), and several say not to use them in type 1. A large tirzepatide trial in type 1 is still running. Small trials found weight loss, but the labels warn low blood sugar is likelier alongside insulin.
What do the labels say about type 1 diabetes?
No label we read lists type 1 diabetes as a use. The approved uses are type 2 diabetes, weight and related conditions.1,2,3,5,6
The US Ozempic and Mounjaro labels list uses in type 2 diabetes only.1,2 The US Zepbound label covers weight and obstructive sleep apnoea.3 Several labels go further. The Australian and Canadian Ozempic and Mounjaro labels say the medicine “should not be used” in type 1 diabetes. The UK Ozempic label says the same.8,10,11,13,14
The EU Ozempic label says semaglutide “is not a substitute for insulin”.5 It reports diabetic ketoacidosis (DKA) in insulin users who stopped or cut insulin quickly. This happened when they started a GLP‑1 medicine.5 The US, EU and Australian Wegovy labels say Wegovy has not been tested in type 1 diabetes.4,7,12
Why does type 1 diabetes make a difference?
In type 1 diabetes the body cannot make insulin. Semaglutide lowers blood sugar partly by making the body release more insulin when sugar is high.16,1 Tirzepatide works in a similar glucose-dependent way.2
The NHS says DKA happens when “a lack of insulin” lets harmful ketones build up in the blood. It usually affects people with type 1 diabetes, and can be life-threatening.17 The NHS also says not to stop or skip insulin, even when you are not eating.17
Low blood sugar is the other risk. The US Ozempic label says lows, including severe ones, are more likely with insulin.1 The US Zepbound label says the same of tirzepatide. Both labels say a lower insulin dose may reduce the risk.1,3
What have trials in type 1 diabetes found?
Trials so far found more weight loss and a small fall in HbA1c. The largest, of an older GLP‑1 medicine, also found more lows. The tirzepatide and semaglutide trials were small.18,19,20
ADJUNCT ONE added liraglutide, an older daily GLP‑1 medicine, or a dummy injection to insulin. It ran for 52 weeks in 1,398 adults.18 At 1.8 mg, HbA1c fell 0.2 points more than on the dummy (range 0.07 to 0.32), and weight 4.9 kg more (range 4.2 to 5.7). Lows with symptoms were about 31% more frequent. High blood sugar with ketones was about twice as frequent.18
ADJUST-T1D gave weekly semaglutide, up to 1 mg, or a dummy to 72 adults for 26 weeks. All had a BMI of 30 or more and an automated insulin pump.19 HbA1c fell 0.3 points more on semaglutide (range 0.05 to 0.6), and weight 8.8 kg more (range 7.0 to 10.6). Each group had 2 severe lows, and nobody had DKA.19
A 12-week trial gave tirzepatide or a dummy to 24 adults with type 1 diabetes and a BMI over 30. Weight fell 8.7 kg more on tirzepatide (range 5.5 to 12.0).20 Daily insulin fell about 35% more (range 21% to 47%).20 The summary reports no significant side effects in either group, but the trial was too small and short to judge the risk of lows or DKA.20 Lilly’s larger trial, SURPASS-T1D-1, has an estimated 905 adults. It is due to finish in December 2026, and no results were posted when we checked.21
A 2025 review of records at one US clinic covered 100 adults with type 1 diabetes on off-label semaglutide or tirzepatide, and 50 on neither. After a year, weight fell 9.1% on semaglutide and 21.4% on tirzepatide, and HbA1c about 0.5 and 0.7 points. It was not a randomised trial, and its summary gives no figures for lows or DKA.23
What do people with type 1 diabetes report on GLP-1 medicines?
From public patient forums: 6 Reddit threads in r/mounjarouk, r/glp1, r/Mounjaro and r/WegovyPillWeightLoss, read in November 2026 (posts from October 2025 to October 2026). Personal reports, not medical evidence.
What people describe
- Matches the trial Many describe needing much less insulin after starting. In the 12-week tirzepatide trial, daily insulin fell about 35% more than on a dummy.20
- Matches the label Many had frequent lows after starting or raising the dose, and had to cut insulin quickly. The US Ozempic and Zepbound labels say lows are more likely with insulin.1,3
- Not studied Several describe lower insulin needs early in the dosing week and higher needs before the next dose. We found no study of this.
Advice people share
- Matches the label Many advise watching glucose closely in the first days and after each dose rise, ready to lower insulin. The US Zepbound label says to monitor blood sugar in diabetes, and that a lower insulin dose may reduce lows.3
- Label says otherwise Many mention people hiding type 1 diabetes or insulin use on online forms. The Canadian Ozempic patient information says to tell your healthcare professional if you have type 1 diabetes.13
- Label says otherwise Several mention stretching injections beyond once a week. The US Zepbound label sets once-weekly doses.3
In your country
No label we read approves either medicine for type 1 diabetes. What differs is whether the label says outright not to use it in type 1.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: Australia’s Ozempic and Mounjaro Product Information say each “should not be used” in type 1 diabetes or to treat DKA. The Wegovy Product Information lists type 1 diabetes as not studied.10,11,12
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: Canada’s Ozempic and Mounjaro monographs say each “should not be used” in type 1 diabetes. The Wegovy monograph says it is “not indicated” for type 1 diabetes.13,14,15
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: France uses the EU labels. The EU Ozempic label says semaglutide is not a substitute for insulin, and the EU Wegovy label lists type 1 as not studied. We found no type 1 statement in the EU Mounjaro label.5,6,7
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: Germany uses the EU labels. The EU Ozempic label says semaglutide is not a substitute for insulin, and the EU Wegovy label lists type 1 as not studied. We found no type 1 statement in the EU Mounjaro label.5,6,7
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We found no public Indian label. This page relies on the US and EU labels.1,2,5,6
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We did not open a Saudi label. This page relies on the US and EU labels.1,2,5,6
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label. This page relies on the US and EU labels.1,2,5,6
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK Ozempic label says semaglutide “should not be used” in type 1 diabetes. We found no type 1 statement in the UK Mounjaro label.8,9
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The US Ozempic and Mounjaro labels list type 2 diabetes uses only, and the Zepbound label covers weight and sleep apnoea. Unlike the Australian, Canadian and UK Ozempic labels, they do not say outright not to use them in type 1. The US Wegovy label says use in type 1 diabetes has not been evaluated.1,2,3,4
Emergency number: 911
Tell your prescriber if you take insulin and get signs of low blood sugar.3 Contact your diabetes team now if blood ketones are 1.6 to 3 mmol/L, or your blood sugar stays high despite insulin.17
Read the full picture
Related questions
Sources
- Novo Nordisk. Ozempic (semaglutide) US prescribing information, sections 1, 5.5 and 12.1. US label. novo-pi.com (PDF)
- Eli Lilly. Mounjaro (tirzepatide) US prescribing information, sections 1 and 12.1. US label. pi.lilly.com (PDF)
- Eli Lilly. Zepbound (tirzepatide) US prescribing information, sections 1, 2, 5.7 and 17. US label. pi.lilly.com (PDF)
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, section 5.4. US label. novo-pi.com (PDF)
- EMA. Ozempic (semaglutide) EU product information, SmPC sections 4.1 and 4.4. EU label. ema.europa.eu (PDF)
- EMA. Mounjaro (tirzepatide) EU product information, SmPC sections 4.1 and 4.4. EU label. ema.europa.eu (PDF)
- EMA. Wegovy (semaglutide) EU product information, SmPC section 4.4. EU label. ema.europa.eu (PDF)
- Novo Nordisk. Ozempic 1 mg (semaglutide) UK Summary of Product Characteristics, section 4.4. UK label. medicines.org.uk (emc)
- Eli Lilly. Mounjaro KwikPen (tirzepatide) UK Summary of Product Characteristics. UK label. medicines.org.uk (emc)
- Novo Nordisk. Ozempic (semaglutide) Australian Product Information, section 4.4. Australian label. medsinfo.com.au (PDF)
- Eli Lilly. Mounjaro (tirzepatide) Australian Product Information, section 4.4. Australian label. medsinfo.com.au (PDF)
- Novo Nordisk. Wegovy (semaglutide) Australian Product Information, section 4.4. Australian label. medsinfo.com.au (PDF)
- Novo Nordisk. Ozempic (semaglutide) Canadian Product Monograph, including patient medication information. Canadian label. pdf.hres.ca (PDF)
- Eli Lilly. Mounjaro (tirzepatide) Canadian Product Monograph, section 1. Canadian label. pdf.hres.ca (PDF)
- Novo Nordisk. Wegovy (semaglutide) Canadian Product Monograph, section 1. Canadian label. pdf.hres.ca (PDF)
- NHS (UK). Type 1 diabetes. nhs.uk
- NHS (UK). Diabetic ketoacidosis. Page last reviewed 8 June 2023 (UK page; the UK emergency number is 999). nhs.uk
- Mathieu C et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016;39(10):1702-10. Sponsored by Novo Nordisk. doi:10.2337/dc16-0691 · PMID 27506222
- Shah VN et al. Semaglutide in adults with type 1 diabetes and obesity (ADJUST-T1D). NEJM Evidence 2025;4(8). Funded by Breakthrough T1D. doi:10.1056/EVIDoa2500173 · PMID 40550013
- Snaith JR et al. Tirzepatide in adults with type 1 diabetes: a phase 2 randomized placebo-controlled clinical trial. Diabetes Care 2026;49(1):161-170. doi:10.2337/dc25-2379 · PMID 41264593
- ClinicalTrials.gov. A study of tirzepatide (LY3298176) compared with placebo in adults with type 1 diabetes and obesity or overweight (SURPASS-T1D-1, NCT06914895). Eli Lilly. Active, not recruiting; estimated enrolment 905; estimated completion December 2026; no results posted. clinicaltrials.gov
- American College of Emergency Physicians. Know When to Go: adult medical emergency symptoms. emergencyphysicians.org
- Snell-Bergeon JK et al. Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes. Diabetes Technology & Therapeutics 2025;27(1):1-9. Retrospective chart review, Barbara Davis Center for Diabetes (US). doi:10.1089/dia.2024.0328 · PMID 39745353
Last checked Nov 16, 2026 · Next review due May 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked between Nov 9 and Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write